Intracavernosal Injections (ICI)
Intracavernosal injection of vasoactive agents directly into the corpus cavernosum produces erection independent of neurogenic stimulation, making ICI the gold standard pharmacotherapy for post-prostatectomy erectile dysfunction when oral PDE5 inhibitors fail. Alprostadil (prostaglandin E1) monotherapy and Trimix (papaverine, phentolamine, alprostadil) are the most commonly used formulations, with efficacy rates of 70–90%.
This atlas page is the practical self-injection / sexual-medicine workflow companion to the full Intracavernosal Injection Agents pharmacology hub.
Indications
| Indication | Why ICI is useful |
|---|---|
| PDE5i failure or contraindication | Direct corporal smooth-muscle pharmacology bypasses impaired NO signaling[1] |
| Post-prostatectomy ED | Works during neuropraxia when oral therapy may be unreliable |
| Severe diabetes / vascular ED | Higher efficacy than oral therapy in many PDE5i non-responders |
| Diagnostic penile duplex Doppler ultrasound | Produces pharmacologic erection for arterial inflow and veno-occlusive assessment |
| Prolonged erection / priapism treatment | Intracavernosal phenylephrine is the rescue drug, not an ED induction agent[2] |
ICI is not just "stronger Viagra." It is a different route with different risks: needle technique, priapism rescue planning, fibrosis surveillance, and adherence support matter as much as the prescription.
Agents & Formulations
| Formulation | Components | Practical role |
|---|---|---|
| Alprostadil | PGE1 | FDA-approved monotherapy; reliable but penile pain can limit use |
| BiMix | Papaverine + phentolamine | Lower pain but often less rigid than TriMix |
| TriMix | Alprostadil + papaverine + phentolamine | Real-world workhorse; roughly 90% success in large series[3] |
| QuadMix | TriMix + atropine | Salvage option after TriMix failure |
| Phenylephrine | Alpha-1 agonist | Priapism / prolonged-erection rescue, dosed and monitored separately[2] |
Combination therapy uses lower doses of each component to improve rigidity while reducing alprostadil-related pain and papaverine-related fibrosis risk.
Technique Overview
- Perform the first injection in the office with dose titration and detumescence monitoring.
- Use a 28- to 30-gauge needle and inject laterally into the proximal or mid-shaft corpus cavernosum.
- Avoid the dorsal neurovascular bundle and ventral urethra.
- Compress the puncture site after injection, especially in anticoagulated patients.
- Rotate sides and injection locations to reduce corporal fibrosis.
- Limit frequency: no more than 3 injections per week and at least 24 hours between injections for alprostadil-label style regimens.
- Give written priapism instructions: a rigid erection approaching 4 hours is an emergency pathway, not a phone-tag problem.
Outcomes & Evidence
ICI efficacy is high, but persistence is the limiting outcome. The AUA ED guideline recommends ICI as second-line therapy and requires in-office testing before home self-injection.[1] Large clinical series report intercourse-capable erections in most users; TriMix has the strongest real-world efficacy signal, with 89% success in a tertiary-center cohort.[3]
The complications to actively prevent are:
- prolonged erection or ischemic priapism,
- penile pain, especially with alprostadil,
- corporal fibrosis / curvature,
- hematoma, especially with anticoagulation,
- dropout from anxiety, cost, or inadequate coaching.
Discontinuation is common early. Front-loaded education, partner involvement when appropriate, and early follow-up after the first home injections are the practical interventions that keep an effective therapy from becoming an abandoned one.
References
1. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004
2. Bivalacqua TJ, Allen BK, Brock G, et al. "Diagnosis and management of priapism: AUA/SMSNA guideline." J Urol. 2022;208(1):43-52. doi:10.1097/JU.0000000000002757
3. Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. "A review of outcomes of an intracavernosal injection therapy programme." BJU Int. 2012;110(11 Pt C):1787-1791. doi:10.1111/j.1464-410X.2012.11266.x